Dementia

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Wednesday, February 28, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acquisition, Neuropharmacology, Morris water navigation task, Dementia, Neuroscience, MWM, Amnesia, IGC, Spatial navigation, Deficit spending, Peptide, Memory, Spatial memory, Patient, LTP, Agitation, Mouse

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.

Animal Biosciences Announces New Canine Clinical Research Evaluating Reversal of Age-Related Signs in Dogs

Retrieved on: 
Tuesday, March 5, 2024
Veterinary, Research, Pets, Clinical Trials, Biotechnology, Health, Consumer, General Health, Science, Pet, Doctor of Philosophy, Dementia, Quality of life, Ageing, Animal, Dog, Neurology, NCSU, Gene expression, Happiness, Cognition, Clinical trial, Frailty, Harvard Medical School, Genetics, BioRxiv, Human, Pharmaceutical industry

Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.

Key Points: 
  • Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.
  • After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, the study shows the first clinical evidence that it is possible to reverse age-related decline in dogs.
  • "The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Dr. Olby noted.
  • In senior dogs, as in humans, this age-related decline can manifest as cognitive decline, increased frailty and lower engagement.

Infusion Nurses Society Adds Vascular Access Safety Devices Such as the Orchid SRV to Standard of Care Guidelines

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Nursing, Managed Care, General Health, Health, Medical Devices, Hospitals, Health Technology, Hospital, BSN, Therapy, Doctor of Philosophy, RN, Orchid, Intravenous therapy, INS, Delirium, Confusion, Standard of care, Risk, Outline of health sciences, Safety, VADS, Deficit spending, Gold, Patient, Dementia, Veterans' affairs, Medical device

Linear Health Sciences , a medical device company that has developed a proprietary, breakaway safety valve platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to encompass devices designed to reduce the risk of vascular access device (VAD) dislodgement, including the Orchid SRV tension-activated breakaway safety release valve.

Key Points: 
  • Linear Health Sciences , a medical device company that has developed a proprietary, breakaway safety valve platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to encompass devices designed to reduce the risk of vascular access device (VAD) dislodgement, including the Orchid SRV tension-activated breakaway safety release valve.
  • The guidelines also flag pediatric patients and those with cognitive issues such as delirium or dementia as being at increased risk for IV dislodgement.
  • The Orchid SRV is a sterile, single-use connector for needle-free access that makes return to treatment fast, simple, and clean, and improves both the patient and clinician experience.
  • Clinical simulation testing of 360 Orchid SRVs showed that the device prevented IV dislodgement by 91.9 percent across all test groups.

Akston Biosciences' AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform's Versatility

Retrieved on: 
Monday, February 26, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Biotechnology, Veterinary, MERS, Dengue fever, Atopic dermatitis, Kinetics, RBD, Vaccination, Immunoglobulin G, Chronic pain, Nerve growth factor, Dementia, Protein, Infection, CGMP, Notifiable disease, Immune system, Vaccine

This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.

Key Points: 
  • This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.
  • Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures and low-cost, high-volume manufacture.
  • AKS-452 is a subunit vaccine consisting of an Fc fusion of the SARS-CoV-2 spike protein receptor binding domain (SP/RBD).
  • “Akston has also made significant strides in demonstrating the Ambifect® platform's potential beyond infectious disease vaccination,” said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

Radisys Unveils Engage Clarity to Enhance Phone Conversations for People Experiencing Hearing Loss

Retrieved on: 
Monday, February 26, 2024
Consumer Electronics, Technology, Health, General Health, Telecommunications, Apps, Applications, Software, Networks, Audio, Video, VoIP, Mobile, Wireless, Friends, Quality of life, Mobile World Congress, Grandparent, World Health Organization, Communication, Risk, Hearing loss, Patient, Dementia, Coffee, Lip, Monolithic kernel, OTT

Hearing difficulties are particularly challenging in phone conversations as telephony is not designed to cater to those with hearing loss, and visual cues like lip reading that can help overcome some hearing difficulties are absent.

Key Points: 
  • Hearing difficulties are particularly challenging in phone conversations as telephony is not designed to cater to those with hearing loss, and visual cues like lip reading that can help overcome some hearing difficulties are absent.
  • Radisys® Corporation , a global leader of open telecom solutions, today announced the availability of Engage Clarity , a unique service that enhances the quality and comprehensibility of voice calls for people with hearing challenges.
  • With global leadership in media processing, Radisys is uniquely positioned to deliver the benefits of Engage Clarity through service providers.
  • Radisys’ Engage Clarity offers a unique entry point for MNOs to help people manage hearing wellness by suggesting regular check-ins with the Engage hearing profile creator when they change their handset or perhaps once a year.

Global IV Catheters Market Insights Report 2023-2029: Peripheral Inserted Central Catheters (PICCs) Leading the Charge - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024
Medical Devices, Health, Diabetes, Incidence, Alzheimer's disease, Infection, ICU, USD, European, Ageing, Growth, Cancer, Conditional sentence, Stroke, Hospital, Government, Short, ICU Medical, Prevalence, Safety, Malaria, Nutrient, PICC, Life expectancy, Injury, Patient, Dementia, Tuberculosis, CVC, Developed country, COPD, Medical device

The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%

Key Points: 
  • The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%
    The global IV catheters market report contains exclusive data on 33 vendors.
  • BD, B Braun, Terumo, Teleflex, ICU Medical, and Nipro Medical are some leading players currently dominating the global IV catheters market.
  • The continuous growth in individuals with chronic conditions and the rapidly expanding elderly population are the primary factors fueling the global demand for peripheral IV catheters.
  • The peripheral inserted central catheters (PICCs) product segment accounted for the highest market share of over 45% of the global CIVCs market.

PhenoSys Now Offers Turnkey Mini2P Systems with poLight ASA Tunable Optics

Retrieved on: 
Wednesday, February 21, 2024
Hardware, Manufacturing, Photography, Technology, Nanotechnology, University, Audio, Video, Education, Neurology, Biotechnology, Science, Software, Veterinary, Research, Health, Engineering, Nobel Prize, Moser research environment, PLT, Systems neuroscience, ASA, Kavli, Dementia, DAQ, Brain

poLight ASA (OSE: PLT) today announced that PhenoSys , a leader in engineering and market innovative technology for animal behaviour research, offers a Mini2P turnkey solution that includes TLens® for optimal microscopic imaging.

Key Points: 
  • poLight ASA (OSE: PLT) today announced that PhenoSys , a leader in engineering and market innovative technology for animal behaviour research, offers a Mini2P turnkey solution that includes TLens® for optimal microscopic imaging.
  • The PhenoSys system includes the miniature two-photon (Mini2P) microscope body for X-Y-Z plane scanning, fiber optics and cabling, two-photon laser, detection unit, flexible DAQ hardware and software, and full technical support.
  • Mini2P is an open-source miniature two-photon microscope brain explorer developed by Kavli Institute for Systems Neuroscience at Norwegian University of Science and Technology.
  • “We are excited to see commercial players suppling the tools and resources to accelerate deployment of Mini2P systems.

The Village at Willow Crossings Resident Care Associate Receives National Recognition for Inspired Caregiving & Service

Retrieved on: 
Thursday, March 7, 2024
Senior living, Woman, Nursing, Alzheimer's disease, Courage, Amnesia, Transport, Empathy, Communication, System, Perseverance, Patient, Dementia, Disorder, Family, News, Mind, Heart, Pub, Village, Environment, Residential care

MANSFIELD, Mass., March 7, 2024 /PRNewswire-PRWeb/ -- The Village at Willow Crossings, a Benchmark senior assisted living and Mind & Memory Care community, today announced that resident care associate, Carol Gordon of Mansfield, has been recognized for her significant contributions to her residents and senior living as a whole. Gordon is one of only four people nationally to be selected for the 2024 McKnight's Women of Distinction Spirit award, a joint program of McKnight's Long-Term Care News, McKnight's Senior Living and McKnight's Home Care.

Key Points: 
  • Since I was young, taking care of older people, and helping to heal those with Alzheimer's, dementia and other disorders has been my life's work."
  • -Carol Gordon, resident care associate, The Village at Willow Crossings
    Now in its sixth year, the award program honors women who have significantly impacted the senior living, skilled nursing or home care fields.
  • The Village at Willow Crossings is the only assisted living community in the greater Mansfield area to have earned U.S. News & World Report Best Senior Living designation.
  • Last year, the assisted living with memory care community earned both Best Assisted Living and Best Memory Care excellence awards.

People with Essential Tremor May Have Increased Risk of Dementia

Retrieved on: 
Wednesday, March 6, 2024
Head, Master of Science, Bangladesh Technical Education Board, Social media, Nervous system, Alzheimer's disease, Arm, Physician, Thought, Stroke, Tremor, Risk, Annual general meeting, DSM-IV codes, Migraine, AAN, Prevalence, Multiple sclerosis, Parkinson's disease, Human, University, Essential tremor, Movement disorder, Dementia, Eating, Concussion, Epilepsy, Diagnosis, Brain, Research, Jaw, American Academy, Pharmaceutical industry

Essential tremor is the most common tremor disorder, more common than Parkinson's disease.

Key Points: 
  • Essential tremor is the most common tremor disorder, more common than Parkinson's disease.
  • "Not only do tremors affect a person's ability to complete daily tasks such writing and eating, our study suggests that people with essential tremor also have an increased risk of developing dementia."
  • The study involved 222 people with essential tremor who had an average age of 79 at the start of the study.
  • "While the majority of people with essential tremor will not develop dementia, our findings provide the basis for physicians to educate people with essential tremor and their families about the heightened risk, and any potential life changes likely to accompany this diagnosis," Louis said.

BrainCheck Secures $15 Million to Fuel Expansion and Adoption of its Next Generation Digital Cognitive Assessment and Care Planning Platform

Retrieved on: 
Wednesday, March 6, 2024
Caregiver, Dementia, New Board, Growth, UPMC, Entrepreneurship, Risk, Deficit spending, Patient, Management

AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- BrainCheck, Inc., a digital health innovator delivering first-of-its-kind technology into the growing digital cognitive assessment market, today announced a $15 million new financing round, led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC. The Company also expanded its Board of Directors with the appointment of Nicholas Shapiro, Vice President, UPMC Enterprises, as a new board member, further strengthening the Company's strategic leadership.

Key Points: 
  • This announcement follows the recent launch of BrainCheck's next generation platform and 3-minute screening solution, which empowers clinicians to screen and monitor patients' cognitive function anytime, anywhere.
  • "We thank our current and new investors for their continued support and look forward to deploying this capital to play an important role in revolutionizing cognitive care."
  • "We believe in BrainCheck's vision to pioneer a fundamental shift in how cognitive care is delivered," said Michael Smerklo, Co-Founder and Managing Partner of Next Coast Ventures.
  • For more information about BrainCheck and its innovative cognitive assessment solutions, please visit www.braincheck.com .